Gastrointestinal biotech Evoke Pharma sets terms for $27 million IPO

By
A A A

Evoke Pharma, a biotech focused on the development of drugs to treat gastrointestinal disorders and diseases, announced terms for its IPO on Friday. The San Diego, CA-based company plans to raise $27 million by offering 2.1 million shares at a price range of $12 to $14. At the midpoint of the proposed range, Evoke Pharma would command a market value of $75 million.

Evoke Pharma, which was founded in 2007, plans to list on the NASDAQ under the symbol EVOK. Evoke Pharma initially filed confidentially on April 19, 2013. Aegis Capital is the sole bookrunner on the deal.




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: EVOK

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

100%

Most Active by Volume

33,110,376
  • $113.99 ▲ 1.77%
25,034,179
    $17.98 unch
24,486,872
  • $7.41 ▲ 2.07%
20,864,535
  • $7.39 ▼ 2.76%
18,600,501
  • $8.30 ▼ 0.36%
17,530,211
  • $8.14 ▲ 3.17%
17,299,208
  • $93.79 ▲ 2.74%
14,669,760
  • $25.78 ▼ 0.19%
As of 12/26/2014, 04:15 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com